Amanda Forys | Managing Partner
Magnolia Market Access
Amanda Forys is Managing Partner at Magnolia Market Access. Her consulting and manufacturer experience has covered a wide range of commercialization topics, including health policy, pricing and rebating, coding, coverage and reimbursement, health economics, budget impact modeling, patient assistance design, and training for specialty pharmaceuticals, biosimilars, organ transplantation, and devices. Amanda often uses quantitative methods for her strategic work, utilizing public and private claims data sources for payment system modeling, budget scoring, and chronic disease studies. Her work, coupled with the invaluable insights gathered by her colleagues through primary and secondary research, provides Magnolia’s clients with a comprehensive look at the marketplace throughout their product’s life cycle.
Appearances:
Pre-Conference Day - World Orphan Drug Congress USA 2026 @ 16:00
Staying Ahead of the Curve: Strategic Responses to a Shifting Policy and Pricing Landscape for Orphan Drug
With ongoing policy changes, many are asking what they mean for orphan drugs. While some initiatives, like demo projects, may seem unrelated, there are significant indirect effects manufacturers must consider.
In this session, we will explore:
- Key policies from CMS and the Trump Administration and their impact on orphan diseases
- The effect of increasing competition on access and implications for orphan drug treatments
- The potential rise of HTA in the U.S.
- How patient assistance programs must evolve to meet the needs of orphan disease patients
- Emerging trends and what to watch for in the coming years
Day 2 - World Orphan Drug Congress USA 2026 @ 14:40
From Value to Volume: Comparing HTA and Market-Driven Pricing for Orphan Drugs in Europe and the United States
Orphan drug pricing takes shape very differently across the Atlantic. In Europe, HTA-driven assessments, value frameworks, and negotiated reimbursement define price and access, while in the United States, a market-driven environment—with limited price controls—creates higher pricing flexibility but broader variation in patient access. This panel will examine how these contrasting systems shape launch strategy, patient availability, long-term sustainability, and incentives for innovation, and what lessons each region can learn from the other.
Objectives:
- Compare the foundational mechanics of orphan drug pricing in the U.S. (market-driven) versus Europe (HTA- and negotiation-driven).
- Evaluate the impact of each system on patient access, coverage timelines, and affordability for rare disease communities.
- Assess how pricing environments influence innovation incentives, manufacturer strategy, and investment in rare disease pipelines.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events